JP2024519322A5 - - Google Patents

Info

Publication number
JP2024519322A5
JP2024519322A5 JP2023568688A JP2023568688A JP2024519322A5 JP 2024519322 A5 JP2024519322 A5 JP 2024519322A5 JP 2023568688 A JP2023568688 A JP 2023568688A JP 2023568688 A JP2023568688 A JP 2023568688A JP 2024519322 A5 JP2024519322 A5 JP 2024519322A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
inhibitor
composition according
agent
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568688A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519322A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/091678 external-priority patent/WO2022237719A1/en
Publication of JP2024519322A publication Critical patent/JP2024519322A/ja
Publication of JP2024519322A5 publication Critical patent/JP2024519322A5/ja
Pending legal-status Critical Current

Links

JP2023568688A 2021-05-11 2022-05-09 併用療法 Pending JP2024519322A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
CN2021093036 2021-05-11
CNPCT/CN2021/093036 2021-05-11
CN2021100523 2021-06-17
CNPCT/CN2021/100522 2021-06-17
CN2021100522 2021-06-17
CNPCT/CN2021/100523 2021-06-17
CN2022086004 2022-04-11
CNPCT/CN2022/086003 2022-04-11
CN2022086003 2022-04-11
CNPCT/CN2022/086004 2022-04-11
PCT/CN2022/091678 WO2022237719A1 (en) 2021-05-11 2022-05-09 Combination therapies

Publications (2)

Publication Number Publication Date
JP2024519322A JP2024519322A (ja) 2024-05-10
JP2024519322A5 true JP2024519322A5 (https=) 2025-05-19

Family

ID=81753153

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568688A Pending JP2024519322A (ja) 2021-05-11 2022-05-09 併用療法

Country Status (16)

Country Link
US (1) US20240261292A1 (https=)
EP (1) EP4337215A1 (https=)
JP (1) JP2024519322A (https=)
KR (1) KR20240006638A (https=)
CN (2) CN117337180A (https=)
AU (1) AU2022271993A1 (https=)
CA (1) CA3214861A1 (https=)
CL (2) CL2023003330A1 (https=)
CO (1) CO2023014325A2 (https=)
DO (1) DOP2023000239A (https=)
IL (1) IL308333A (https=)
MX (1) MX2023013436A (https=)
PE (1) PE20240588A1 (https=)
TW (1) TW202308642A (https=)
UY (1) UY39762A (https=)
WO (1) WO2022237719A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202525813A (zh) 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物
EP4626426A1 (en) * 2022-11-30 2025-10-08 JANSSEN Pharmaceutica NV Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent
WO2024114666A1 (en) * 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor
EP4698182A1 (en) * 2023-04-17 2026-02-25 Janssen Pharmaceutica NV Combination of a menin-ll1 inhibitor, a dna intercalating agent and a pyrimidine analogue to treat a hematopoietic disorder
WO2025082444A2 (en) * 2023-10-20 2025-04-24 Janssen Pharmaceutica Nv (r) -n-ethyl-5-fluoro-n-isopropyl-2- ( (5- (2- (6- ( (2-methoxyethyl) (methyl) amino) -2-methylhexan-3-yl) -2, 6-diazaspiro [3.4] octan-6-yl) -1, 2, 4-triazin-6-yl) oxy) benzamide, formulations and dosage regimens thereof, for use in treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2017000080A1 (en) 2014-12-18 2018-07-04 Takeda Pharmaceuticals Co Solid state forms of fused heteroaromatic pyrrolidinones
WO2017214367A1 (en) * 2016-06-10 2017-12-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
WO2018175746A1 (en) * 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
JP2022503792A (ja) * 2018-09-26 2022-01-12 クラ オンコロジー，インク． メニン阻害剤を用いた血液悪性腫瘍の処置
TW202104207A (zh) 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
TW202525813A (zh) 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物

Similar Documents

Publication Publication Date Title
JP2024519322A5 (https=)
JP2024518497A5 (https=)
US20220241261A1 (en) Combinations of inhibitors of irak4 with inhibitors of btk
CN110621316B (zh) 用ehmt2抑制剂进行的组合疗法
US6838467B2 (en) Dosing regimen
US12350265B2 (en) Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents
JP2003525252A (ja) Ｈｅｒ２抗体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
JP2002519389A (ja) インビボ放射線増感特性をもつファルネシルタンパク質トランスフェラーゼ阻害剤
JP2003525238A (ja) 抗腫瘍性ポドフィロトキシン誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
US20030078281A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents
US20030186925A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
EP3941921A1 (en) Therapeutic methods for treating hepatitis b
EP4000624A1 (en) Btk inhibitors for treating splenomegaly
JP2003525245A (ja) ファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
KR20210092204A (ko) 비산트렌 제형의 제조 및 전달을 위한 방법
JP2003525237A (ja) 抗腫瘍性アントラサイクリン誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
Chu et al. Basic and clinical pharmacology
US11642343B2 (en) Methods of treating splenomegaly
KR20240144146A (ko) Malt1 저해약을 유효 성분으로서 포함하는 암 치료제
JP2026510567A (ja) 血液悪性腫瘍の治療におけるロギノリシブ及びｂｃｌ－２阻害剤の組み合わせ
EP4228645A1 (en) Combinations of bcl-2 inhibitors with chemotherapeutic agents
HK40078282A (en) Btk inhibitors for treating splenomegaly
KR20250054051A (ko) Bcl-2 억제제를 포함한 암 병용 요법
JP2023061488A (ja) 組み合わせ医薬として用いられるメニン－ｍｌｌ阻害剤を含有する医薬組成物
HK40063890A (en) Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents